Acute myeloid leukemia (AML) is an invasive hematopoietic malignancy requiring novel treatment strategies. The PDE3A inhibitor anagrelide (ANA) profoundly suppresses the proliferation of high PDE3A-ex
A549 cells were exposed for 1 h and 2 h with 10 µM and 50 µM trypacidin, then the medium containing trypacidin was replaced by fresh medium and cell viability was measured 24 h later using MTT assay.
Acute myeloid leukemia (AML) is a malignant hematopoietic disease with poor prognosis for most patients. Conventional chemotherapy has been the standard treatment approach for AML in the past 40 years
